A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast

NCT04481763 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Triple-Negative Breast Cancer

Interventions

DRUG: Camrelizumab
RADIATION: radiotherapy

Sponsor

Jiangxi Provincial Cancer Hospital